Sponsored Sessions

From Lab to Lizzy – the Australian story behind eosinophils 

Sunday Breakfast Session
Time: 0700 - 0815 (breakfast from 0700, presentation starts 0715)
Venue: Meeting Room 211


Reframing Asthma Care ‐ New Approaches in Asthma Management 

Sunday Evening Symposium
Time: 1730 - 1915 (networking drinks from 1730, presentation starts 1745)
Venue: Meeting Room 211


New directions in severe asthma management 

Monday Evening Symposium
Time: 1730 - 1915 (networking drinks from 1730, presentation starts 1745)
Venue: Meeting Room 211
Chairperson: Professor Christine Jenkins
Speakers: Professor John Upham, Professor Christine Jenkins and Professor Liam Heaney

Comorbidities in asthma (Prof Christine Jenkins)
Asthma is often not considered as a disease that has multiple comorbidities apart from those directly linked to having an atopic or T2 high predisposition. Related airway focused conditions such as intermittent laryngeal obstruction, bronchiectasis, dysfunctional breathing and COPD-asthma overlap are also often included in considerations of asthma comorbidities, but systemic, standalone comorbid conditions are often overlooked or considered to affect only a small proportion of patients. This talk will present the data that shows that asthma is associated with airway, breathing and systemic comorbidities that can affect treatment response and should be addressed to achieve best outcomes for asthma management.

Type 2 asthma, its variants and response to therapy (Prof John Upham)
Type 2 inflammation is present in many people with severe asthma. A number of novel therapies targeting specific type 2 cytokines and inflammatory mediators have emerged in recent years, revolutionising severe asthma management. However, it is also clear that type 2 asthma is not homogenous, with some patients exhibiting a predominantly allergic phenotype, whereas others show a strong eosinophilic, non-allergic phenotype. Understanding the biological basis for these phenotypic variants, and the variable responses to different targeted therapies, is key to making rational treatment choices.

Where does Dupilumab fit into severe asthma management (Prof Liam Heaney)
Dupixent is a human monoclonal antibody that inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines that play a central role in type 2 inflammation that underlies specific types of asthma as well as several other allergic diseases. Dupixent is indicated in Australia for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for chronic systemic therapy,not indicated for episodic use. Dupixent is also indicated  for add on maintenance treatment in patients aged 12 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO). It is indicated as maintenance therapy for oral corticosteroid dependent asthma. This talk will discuss Dupilumab utilities  and provide practical guidance on its clinical use in severe asthma management.